ArticleFrontiers in molecular biosciences2025
Effect of antagomir-22-3p treatment on skeletal muscle growth in intrauterine growth-restricted lambs.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Different Pattern in Circulating MicroRNA-22-3p Levels Between Patients With Primary Versus Secondary Sarcopenia.Aging cell · 2025Article
- Mandibular extracellular vesicles mediate morphogenesis and mineralization of tooth germs in miniature swine through the miR-206/HDAC4 signaling axis.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: MicroRNAs (miRNAs) play a crucial role in regulating gene expression and muscle development. Previous research identified miR-22-3p as being differentially regulated during muscle hypertrophy, and Methods: Pregnant ewes (n = 18) carrying twins were fed either 100% of NRC (CON) or were nutrient-restricted to 60% NRC (NR) from gestational d 86 until parturition. On d 12 of age, NR lambs (n = 8) were randomly selected and given a systemic injection of antagomir-22-3p (440 µg/lamb) into the lateral saphenous vein of the right leg (NR-ANT22) for three consecutive days. CON lambs (n = 8) were also randomly selected and received a sham injection of phosphate-buffered saline (PBS) into the lateral saphenous vein of the right leg (CON-SHAM). Blood samples were collected from each lamb weekly to monitor circulating miR-22-3p expression. Muscle samples were collected 24 days post-injection to assess miR-22-3p levels and mRNA expression of potential miRNA targets. Results and discussion: Cell-free circulating miR-22-3p expression was more downregulated (P < 0.05) in NR-ANT22 lambs compared to that in CON-SHAM on d 14 after injection. On d 21 after injection, miR-22-3p expression in plasma tended to be more downregulated (P = 0.08) in NR-ANT22 compared to CON-SHAM. Lamb body weight and muscle weights at harvest were similar between the NR-ANT and CON- SHAM treatment groups. In the semitendinosus (ST) muscle, miR-22-3p expression was more downregulated (P < 0.05) in NR-ANT22_R ST (treated) lambs compared to that in NR-ANT22_L ST (non-treated) and CON-SHAM ST. In the heart and semimembranosus (SM) muscles, the expression of miR-22-3p was more downregulated (P < 0.05) in NR-ANT22 compared to that in CON-SHAM. In the gastrocnemius muscle, miR-22-3p expression remained unchanged (P > 0.05). The number of types I, IIa, and IIax muscle fibers were greater (P < 0.05) in NR-ANT22 lambs than those in CON-SHAM, whereas the number of type IIx fibers was greater (P < 0.05) in CON-SHAM lambs. NR-ANT22 treatment appears to promote a shift toward more oxidative muscle fiber metabolism. The systemic injection of antagomir-22-3p downregulated miR-22-3p expression in circulation and muscle tissues, which, in turn, altered the expression of HDAC/SIRT genes involved in muscle fiber type conversion and hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.